All In Biotech

Drug Trial Radar · NCT03462498

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent

Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,008 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,008

Actual

Start

Apr 2, 2018

Primary completion

Dec 31, 2021

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Kyoto University, Graduate School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).

Conditions

  • Acute Coronary Syndrome
  • Acute Myocardial Infarction
  • Coronary Artery Disease
  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors

Interventions

  • 1-months DAPTDrug

    1-month DAPT followed by 59-month monotherapy

  • 12-month DAPTDrug

    12-month DAPT followed by 48-month monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study groupTime frame: 12 months
  2. Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study groupTime frame: 60 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyoto University Graduate School of Medicine

    Kyoto, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.